CD274 and neoplasm: Thus, in addition to PD-L1 expression, other predictive biomarkers for immunotherapy are under investigation, including tumor mutational burden, immune-related gene expression analysis, circulating tumor DNA, and the tumor microenvironment, including tumor-infiltrating lymphocytes (TILs) [8,10,12,13].